Intensity Therapeutics (INTS) grants 5,500-share stock option to director
Rhea-AI Filing Summary
Intensity Therapeutics director Donovan Daniel received a stock option grant for 5,500 shares of common stock on July 16, 2026. The option has an exercise price of $4.90 per share, expires on July 16, 2036, and vests in four equal annual installments starting July 16, 2026, subject to continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Donovan Daniel
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy Common Stock) F1 | 5,500 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy Common Stock) — 5,500 shares (Direct)
Footnotes (1)
- F1. This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on July 16, 2026.
Key Figures
Stock options granted: 5,500 shares
Exercise price: $4.90 per share
Expiration date: July 16, 2036
+1 more
4 metrics
Stock options granted
5,500 shares
Stock Option grant to director on July 16, 2026
Exercise price
$4.90 per share
Exercise price of stock option granted July 16, 2026
Expiration date
July 16, 2036
Expiration of stock option granted to director
Vesting schedule
4 equal annual installments
Option vests annually beginning July 16, 2026, subject to continued service
Key Terms
Stock Option (right to buy Common Stock), exercise price, vesting
3 terms
Stock Option (right to buy Common Stock) financial
"security title "Stock Option (right to buy Common Stock)""
exercise price financial
"conversion or exercise price of 4.9000 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"This option will vest in four, equal, annual installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Intensity Therapeutics (INTS) report for Donovan Daniel?
Intensity Therapeutics reported that director Donovan Daniel received a stock option grant for 5,500 shares on July 16, 2026. The option is a right to buy common stock at a fixed exercise price, providing equity-based compensation linked to future company performance.
How does the vesting schedule work for the Intensity Therapeutics (INTS) option grant?
The option will vest in four equal annual installments, beginning on July 16, 2026, subject to Donovan Daniel’s continued service with Intensity Therapeutics. Each year, one-quarter of the 5,500-option grant becomes exercisable until fully vested after four years.
When does the newly granted INTS stock option to Donovan Daniel expire?
The stock option granted to director Donovan Daniel has an expiration date of July 16, 2036. After that date, any unexercised portion of the 5,500 underlying shares can no longer be purchased at the $4.90 exercise price specified in the grant terms.
What is the difference between the transaction price and exercise price in the INTS Form 4?
The reported transaction price per option share is $0.00, reflecting a grant rather than a purchase, while the exercise price is $4.90 per share. The exercise price is what must be paid per share if and when the option is exercised in the future.
How many derivative securities does Donovan Daniel hold in INTS after this option grant?
Following this grant, the Form 4 shows 5,500 derivative securities held directly by Donovan Daniel, corresponding to the newly awarded stock option. These represent rights to acquire an equal number of Intensity Therapeutics common shares, subject to vesting and the 2036 expiration date.